Výsledky vyhledávání - "Thomas M Cardillo"

Akademický článek

Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer

Autor: Jayakumar R. Nair, Tzu-Ting Huang, Anu Sunkara, Margaret R. Pruitt, Kristen R. Ibanez, Chih-Yuan Chiang, Ken Chih-Chien Cheng, Kelli Wilson, Thomas M. Cardillo, Scott Hofsess, Jung-Min Lee

Publikováno v: iScience, Vol 27, Iss 12, Pp 111283- (2024)

Summary: Antibody–drug conjugates (ADCs) have become an important class of anticancer drugs in solid tumors including drug-resistant gynecologic malignancies. TROP2 is a cell surface antigen that is highly expressed in ovarian carcinoma (OC) but mi

Externí odkaz: https://doaj.org/article/3a64168110b4462697098b3affe9423a

Zobrazit plný text záznamu

Akademický článek

Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.

Autor: Donglin Liu, Chien-Hsing Chang, Edmund A Rossi, Thomas M Cardillo, David M Goldenberg

Publikováno v: PLoS ONE, Vol 8, Iss 5, p e63940 (2013)

The type III interferons (IFNs), comprising IFN-λ1, IFN-λ2, and IFN-λ3, behave similarly to IFN-α in eliciting antiviral, antitumor, and immune-modulating activities. Due to their more restricted cellular targets, IFN-λs are attractive as potent

Externí odkaz: https://doaj.org/article/7f9bd00b954b407a9b485765cb23f968

Zobrazit plný text záznamu

Akademický článek

A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.

Autor: Chien-Hsing Chang, Jorma Hinkula, Meiyu Loo, Tina Falkeborn, Rongxiu Li, Thomas M Cardillo, Edmund A Rossi, David M Goldenberg, Britta Wahren

Publikováno v: PLoS ONE, Vol 7, Iss 7, p e41235 (2012)

We constructed novel HIV-1 fusion inhibitors that may overcome the current limitations of enfuvirtide, the first such therapeutic in this class. The three prototypes generated by the Dock-and-Lock (DNL) technology to comprise four copies of enfuvirti

Externí odkaz: https://doaj.org/article/19a5fbd54d4f4735ac2851376c9050f1

Zobrazit plný text záznamu

Akademický článek

Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines.

Autor: Chien-Hsing Chang, Yang Wang, Preeti Trisal, Rongxiu Li, Diane L Rossi, Anju Nair, Pankaj Gupta, Michele Losman, Thomas M Cardillo, Edmund A Rossi, David M Goldenberg

Publikováno v: PLoS ONE, Vol 7, Iss 8, p e44235 (2012)

A major mechanism of monoclonal antibodies that selectively target the insulin-like growth factor type 1 receptor (IGF-1R) to inhibit tumor growth is by downregulating the receptor, regardless whether they are capable (antagonistic) or incapable (ago

Externí odkaz: https://doaj.org/article/911314e583d9433abb57d0f3190e46a9

Zobrazit plný text záznamu

Data from Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

Autor: David M. Goldenberg, Chien-Hsing Chang, Edmund A. Rossi, Jing Xia, Jennifer Donnell, Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey

Labetuzumab govitecan (IMMU-130), an antibody–drug conjugate (ADC) with an average of 7.6 SN-38/IgG, was evaluated for its potential to enhance delivery of SN-38 to human colonic tumor xenografts. Mice bearing LS174T or GW-39 human colonic tumor xe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::584782adb04055b72f2de9e67090ec97
https://doi.org/10.1158/1535-7163.c.6538041.v1

Zobrazit plný text záznamu

Supplementary Table S1 from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

Autor: David M. Goldenberg, David V. Gold, Fatma Tat, Robert M. Sharkey, Thomas M. Cardillo, Serengulam V. Govindan

PDF file - 59 KB, Reversed-phase HPLC analyses of cathepsin B incubates and buffer control incubates of ME-CL2E-SN-38, pH 5, 37 degrees Celsius. Values represent % of applied product.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46356aa29535a12d317021217a23259f
https://doi.org/10.1158/1535-7163.22500250.v1

Zobrazit plný text záznamu

Data from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

Autor: David M. Goldenberg, David V. Gold, Fatma Tat, Robert M. Sharkey, Thomas M. Cardillo, Serengulam V. Govindan

CD74 is an attractive target for antibody–drug conjugates (ADC), because it internalizes and recycles after antibody binding. CD74 mostly is associated with hematologic tumors but is expressed also in solid cancers. Therefore, ADCs of the humanized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e648ecf567c521d924f6481502a382b
https://doi.org/10.1158/1535-7163.c.6536407.v1

Zobrazit plný text záznamu

Data from IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

Autor: David M. Goldenberg, Chien-Hsing Chang, Yang Wang, Diane L. Rossi, Maria B. Zalath, Serengulam V. Govindan, Thomas M. Cardillo

HLA-DR is a member of the MHC class II antigen family expressed on hematologic and solid tumors. Antibodies directed against HLA-DR have demonstrated some clinical success, but toxicities limited development. IMMU-140 is an anti–HLA-DR antibody–d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::379d0d89af3cea5f958795f16cd8a214
https://doi.org/10.1158/1535-7163.c.6537790.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání